Acquisition by Alexander Arrow of 8000 shares of Protagenic Therapeutics at 0.81 subject to Rule 16b-3
| PTIX Stock | USD 0.65 0.04 6.56% |
Slightly above 72 percent of all Protagenic Therapeutics' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Protagenic Therapeutics suggests that a large number of traders are confidant. Protagenic Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Protagenic Therapeutics' earnings reports, geopolitical events, and overall market trends.
Protagenic |
Filed transaction by Protagenic Therapeutics Officer Chief Financial Officer. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Protagenic Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Protagenic Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Protagenic Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Protagenic Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Protagenic Therapeutics Fundamental Analysis
We analyze Protagenic Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Protagenic Therapeutics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Protagenic Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Protagenic Therapeutics stock to make a market-neutral strategy. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics with similar companies.
Peers
Protagenic Therapeutics Related Equities
| ANTX | AN2 Therapeutics | 8.94 | ||||
| TPST | Tempest Therapeutics | 2.25 | ||||
| AVTE | Aerovate Therapeutics | 1.92 | ||||
| ACRV | Acrivon Therapeutics, | 1.71 | ||||
| RZLT | Rezolute | 1.03 | ||||
| SBHMY | Sino Biopharmaceutica | 0.00 | ||||
| XOMAO | XOMA | 0.32 | ||||
| ELDN | Eledon Pharmaceuticals | 1.47 | ||||
| ADAG | Adagene | 3.10 |
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.